US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Lipidor updates on Phase III study of AKP02 in treatment of psoriasis – half of patients now recruited

STOCKHOLM, Sweden, 20 May 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase III study of AKP02 skin spray for mild to moderate psoriasis, with the last patient expected to begin treatment in June 2022. Topline results from the Phase III study are expected during the third quarter of 2022.On 26 January, Lipidor announced that the first psoriasis patients had been enrolled in the company's Phase III clinical trial of AKP02 cutaneous spray. The observer-blind and placebo-controlled Phase III study included

Lipidor AB (publ) publishes interim report for first quarter 2022

STOCKHOLM, Sweden, 5 May 2022 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period 1 January – 31 March 2022. The report is available on the company's website lipidor.se  and in the attached pdf.Summary of year-end report During the first quarter, the first patients were enrolled in a Phase III clinical trial with AKP02 cutaneous spray for mild to moderate psoriasis. The study will be carried out during the first half of 2022. The subsidiary Emollivet AB has launched COMBI -

NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (publ)

STOCKHOLM, Sweden, 3[rd] May 2022: The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (“Lipidor” or the “Company”) are hereby given notice of the Annual General Meeting (the “AGM”) to be held on 2 June 2022.N.B. This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Lipidor’s annual general meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. There will be no meeting with the possibility to attend in person or to be represented by a proxy. Lipidor welcomes

Lipidor strengthens its operational team and recruits Supply Chain & Operations Manager

STOCKHOLM, Sweden, 25 March 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) is announcing that the company has strengthened its operational team with the recruitment of Marianne Avila to the position of Supply Chain & Operations Manager.At Lipidor, Marianne Avila will strengthen the operational team and contribute to development, primarily in purchasing and logistics, which are vital functions as the company approaches commercialization. Lipidor already has a commercial agreement in place, and work is underway for additional commercial contracts, for the company's drug

Lipidor AB (publ) publishes year-end report for 2021

STOCKHOLM, Sweden, 23 February 2022 – Today, Lipidor AB publishes its year-end report for the period 1 January – 31 December 2021. The report is available on the company's website lipidor.se  and in the attached pdf.Summary of year-end report During the year, Lipidor's most important milestone to date was reached when a commercially exclusive agreement for registration, marketing, sales and distribution of AKP01 and AKP02 was signed with RELIFE S.r.l - part of a leading international pharmaceutical company, Menarini Group. In

Lipidor Announces Enrolment of First Patients in a Phase III Study on AKP02 for Treatment of Psoriasis

STOCKHOLM, Sweden, 26[th] January 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today reports that the first patients have been enrolled in a Phase III clinical study using AKP02 cutaneous spray (calcipotriol + betamethasone dipropionate 0.005 %/0.05 %) against mild to moderate psoriasis. Results from the study are expected to be presented in Q2 2022.The observer-blind and placebo-controlled Phase III clinical study with AKP02 comprises a total of 294 patients and is being conducted at 13 clinics in India. The trial is fully funded with existing funds and is conducted by

Lipidor expands clinical program, announces investment in new drug development project against acne vulgaris

STOCKHOLM, 17[th] December 2021 – Lipidor AB (publ) (Nasdaq First North: LIPI) today announces that it has initiated a preclinical program for a new drug candidate, AKP-08, focused on acne vulgaris (acne). The market for acne medicines amounts to about 35 billion SEK per year, which together with the clinical needs relating to acne makes it a very attractive indication to invest in.Acne vulgaris occurs in up to 96% of all adolescents and around 15% of those suffer from moderate or severe acne, which often causes major problems for the sufferer. Lipidor has, together with leading acne

Lipidor presents Nomination Committee

STOCKHOLM, 9[th] December 2021 – In accordance with the current nomination committee instructions for Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI), as resolved by the AGM 2020, Lipidor shall have a nomination committee consisting of four members.The three largest shareholders who are registered with Euroclear Sweden AB on the last day of September before the meeting are to be contacted by the company's Chairman of the Board. The three largest shareholders each have the right to appoint a member of the Nomination Committee. In addition, the Chairman of the Board shall be a

Lipidor publishes interim report for period 1 January - 30 September and Q3 2021

STOCKHOLM, Sweden, 25[th] November 2021: Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period July – September 2021. The quarterly report is available on the company's website (click here ) and in the attached pdf.Summary of the interim report – third quarter 2021 The quarter saw Lipidors most important milestone to date when we entered into an exclusive commercial agreement for registration, marketing, sales and distribution of AKP01 and AKP02 with RELIFE S.r.L. – part of the

Lipidor submits new patent application and expands collaboration with Cannassure using Lipidor’s AKVANO[®] technology for medicinal cannabis products

Stockholm, Sweden, 29 October 2021 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announced that the collaboration agreement with Cannassure Therapeutics has expanded to include a new patent family covering new innovative AKVANO[®] topical compositions. Lipidor submitted the new patent application to the European Patent Office on 25 October 2021.Earlier this year, Lipidor signed an exclusive licensing agreement with Cannassure Therapeutics for the use of Lipidor’s patented drug delivery technology AKVANO[® ]in topical medical cannabis products, and the programs are

Warrant holders exercise all warrants in Lipidor’s incentive program 2018/2021

STOCKHOLM, Sweden, 19 October 2021 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the Company’s LTI 2018/2021, which was addressed to CEO Ola Holmlund and Senior Scientist Vibhu Rinwa and which includes 580,000 warrants, with an exercise period during the period 1 - 30 October 2021, has been terminated and that all warrants have been exercised. The exercise price amounted to SEK 2 per share, meaning that Lipidor, through the share subscription, will receive SEK 1.16 million.On 10 September 2018, the  Board of Lipidor decided, with the authorization of the

Lipidor announces approval to start Phase III clinical study of drug candidate AKP02 for treatment of psoriasis

STOCKHOLM, Sweden, September 27, 2021: Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that the company’s Phase III clinical study of its drug candidate AKP02 for the treatment of psoriasis has been approved by the Indian Medical Products Agency and is ready to start. The main purpose of the study is to compare the therapeutic efficacy of AKP02 with Enstilar, the current market leader, for mild to moderate psoriasis. As Lipidor previously announced, results from the study are expected in the first half of 2022.The registration-based Phase III clinical study with

Lipidor publishes interim report for H1 2021

STOCKHOLM, Sweden, 24[th] August 2021: Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January – June 2021. The quarterly report is available on the company's website (click here ) and in the attached pdf (in Swedish).Summary of the interim report – second quarter 2021 Lipidor has had an intense first half year with success in many areas. At the beginning of the year, we signed a license agreement with Cannassure Therapeutics (for topical medical cannabis products based on

Summer letter from Lipidor

STOCKHOLM, Sweden, 6 July 2021: CEO Ola Holmlund comments on the year’s progress so far and the recent commercial license agreement with the Menarini Group’s subsidiary RELIFE.The first half of this year has been an intensive period in several areas. In the beginning of the year, we signed a license agreement with Cannassure Therapeutics (for topical medical cannabis products based on Lipidor’s AKVANO® technology) as well as submitted an application regarding the start of the Phase III clinical trial with our combination drug candidate for the treatment of psoriasis (AKP02). Furthermore,

Lipidor AB licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70

STOCKHOLM, Sweden, 30 June 2021: Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that it has signed a licence agreement under which Lipidor grants RELIFE S.r.l., part of leading international pharmaceutical company, Menarini Group, exclusive rights to register, promote, distribute, and market drug candidates for the treatment of psoriasis in EU, Turkey, UK, Switzerland, CIS, and Balkan countries. The total potential value of this agreement is up to MEUR 70.Under the terms of this agreement, RELIFE S.r.l., a clinical dermatology therapeutics and aesthetic medicine

Bulletin from the Extraordinary General Meeting of Lipidor AB (publ)

STOCKHOLM, Sweden, 8 June 2021: The following resolutions were passed at the extraordinary general meeting (the “EGM”) of Lipidor (publ) (the “Company”) on 8 June 2021. Due to the covid-19 pandemic, the Company’s extraordinary general meeting was carried out through advance voting (postal voting) only.Incentive programme in the subsidiary Emollivet AB The EGM resolved, in accordance with the Board of Directors’ proposal, to approve of the subsidiary Emollivet AB’s resolution to adopt an incentive programme to the management in Emollivet AB consisting of warrants. In short, the incentive

Bulletin from the annual general meeting of Lipidor AB (publ)

STOCKHOLM, Sweden, 8 June 2021: The following resolutions were passed at the annual general meeting (the “AGM”) of Lipidor (publ) (the “Company”) on 8 June 2021. Due to the covid-19 pandemic, the Company’s annual general meeting was carried out through advance voting (postal voting) only.Adoption of income statement and balance sheet and discharge from liability The AGM resolved to adopt the income statement for the financial year 2020 as well as the balance sheet and consolidated balance sheet as of 31 December 2020. The members of the board of directors and the managing director were

NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (publ)

STOCKHOLM, Sweden, 24 May 2021: The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (the “Company” or “Lipidor”) are hereby given notice of the Extraordinary General Meeting (the “EGM”) to be held on 8 June 2021.N.B. This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Due to the extraordinary situation relating to the covid-19 pandemic, Lipidor’s extraordinary general meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. There will be no meeting with the

NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (publ)

STOCKHOLM, Sweden, 7th May 2021: The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (“Lipidor” or the “Company”) are hereby given notice of the Annual General Meeting (the “AGM”) to be held on 8 June 2021.N.B. This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Due to the extraordinary situation relating to the covid-19 pandemic, Lipidor’s annual general meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. There will be no meeting with the possibility to

Lipidor publishes interim report for Q1 2021

STOCKHOLM, Sweden, 6 May 2021: Today, Lipidor AB (publ) (Nasdaq First North: LIPI) publishes its interim report for the period January – March 2021. The quarterly report is available on the company's website (click here ) and in the attached pdf (in Swedish).Summary of the interim report – first quarter 2021 The period began with a signed license agreement with Cannassure Therapuetics Ltd, regarding medical cannabis products based on Lipidor's AKVANO® technology. Activities prior to the start of the Phase III study with AKP02, and

Lipidor's subsidiary Emollivet takes the next step towards launch and receives funding from Vinnova

Stockholm, Sweden, 23 April 2021 – Sweden's innovation authority Vinnova is investing in Lipidor's subsidiary Emollivet. The funding from Vinnova is for SEK 300,000 and will be used for a project in which Emollivet, through interaction with animal owners and others in the animal health market, will gather data for the upcoming launch.Emollivet develops animal care products based on Lipidor's patented AKVANO technology. The company was funded in 2020 to focus on commercializing animal care products. Since Stina Linge was recruited as CEO last autumn, development in Emollivet has accelerated.

There are no items matching the current filter
There are no more items matching the current filter
Back to top